Siga Technologies, a US biopharmaceutical company that focuses onantibiotics and vaccines, has begun trading on the Frankfurt Stock Exchange in Germany. The company's chairman, Donald Drapkin, said the new listing "is a notable achievement which will assist us in the fulfillment of our strategic positioning in the global financial marketplace," and claimed that it will enhance Siga's international exposure.
Chief executive Philip Sussman said that the company is "officially kicking off our listing with a multi-city road show to formally introduce Siga to the investment community on the continent."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze